Home » Topics » BioWorld Science

BioWorld Science
RSS

Aclaris offers update on clinical trials of JAK1/3 inhibitors ATI-502 and ATI-501

Dec. 18, 2018

Ovid Therapeutics presents phase Ib/IIa data for OV-935 in adults with rare epilepsies

Dec. 18, 2018

Alkahest reports promising data from two phase IIa studies of AKST-4290 in wet AMD

Dec. 18, 2018

Ayala initiates phase II study of AL-101 in adenoid cystic carcinoma with Notch activated mutations

Dec. 18, 2018

China becomes first country to approve roxadustat

Dec. 18, 2018

Rakuten Aspyrian opens enrollment in phase III trial of ASP-1929 for head and neck cancer

Dec. 18, 2018

Initiation of pivotal phase III program of TWIN for acne vulgaris

Dec. 18, 2018

Phase III obesity registration trial of tesofensine meets primary and secondary endpoints

Dec. 18, 2018

BeiGene initiates two global phase III studies of tislelizumab

Dec. 18, 2018

Topline results presented from phase I study of XCUR-17 in chronic plaque psoriasis

Dec. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...